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PRAGMATISM OF RANDOMIZED
CLINICAL TRIALS ON RANIBIZUMAB FOR
THE TREATMENT OF DIABETIC
MACULAR EDEMA
Impact on Clinical Outcomes
STEPHEN STEWART, MA, MBBS, FRCOPHTH,† JIAN LEE YEONG, MBCHB,† GIANNI VIRGILI, MD,†
AUGUSTO AZUARA-BLANCO, MD, PHD, FRCOPHTH,‡ NOEMI LOIS, MD, PHD, FRCS(ED), FRCOPHTH*†
Purpose: To evaluate the pragmatism and generalizability of randomized clinical trials
(RCTs) on ranibizumab for diabetic macular edema and determine whether clinical outcomes
would differ based on whether or not patients fulﬁll the eligibility criteria of these RCTs.
Methods: Pragmatism and generalizability of three RCTs on ranibizumab for diabetic
macular edema (DRCRnet Protocols I and T, and RESTORE) were rated using the PRECIS-
2 tool. A cohort of consecutive patients with diabetic macular edema was assessed to
determine whether clinical outcomes differed based on whether or not patients met the
RCT eligibility criteria. Univariable and multivariable regression analyses, adjusted for
baseline best-corrected visual acuity, central retinal thickness and number of injections
received, were used.
Results: All RCTs were rated as being more pragmatic than explanatory, with DRCRnet trials
being the most pragmatic. Of the 216 eyes (176 patients) included in the cohort, 63%would have
met eligibility criteria for Protocol T, 61% for Protocol I, and 56% for RESTORE. When adjusted
for best-corrected visual acuity, central retinal thickness, and number of ranibizumab injections
received, there were no statistically signiﬁcant differences in best-corrected visual acuity or
central retinal thickness found between “eligible” and “ineligible” patients.
Conclusion: Randomized clinical trials evaluating ranibizumab for diabetic macular
edema were more pragmatic than explanatory. “Ineligible” patients still beneﬁted from
ranibizumab therapy.
RETINA 00:1–9, 2019
Visual loss due to diabetic macular edema (DME) isa common complication of diabetic retinopathy,
with an estimated global prevalence of 6.8% in all
individuals with diabetes.1–3 Several randomized
clinical trials (RCTs) found intravitreal injection
of ranibizumab to be effective for the treatment of
DME4–6 and more efﬁcacious than macular laser
photocoagulation.7,8 The National Institute for Health
and Care Excellence in the United Kingdom appraised
ranibizumab for the treatment of DME.9 The National
Institute for Health and Care Excellence found ranibizu-
mab to be cost-effective only for patients with DME and
central retinal thickness (CRT) of $400 mm. In patients
with CRT,400 mm, laser prevailed, and macular laser is
therefore recommended and remains the treatment of
choice for this group of patients with DME in the United
Kingdom.
Properly designed and adequately conducted RCTs are
considered to provide the best-available evidence to guide
patient care, only surpassed by meta-analysis and indi-
vidual participant data meta-analysis of randomized trials.
Randomized trials can be designed as pragmatic or
explanatory.10 Pragmatic RCTs are primarily designed
to determine the effectiveness of an intervention under
the usual conditions in which this intervention will be
applied.11 By contrast, explanatory trials are designed to
determine the efﬁcacy of an intervention under ideal cir-
cumstances; known biases and confounders are meticu-
lously controlled for to maximize the ability to reveal any
therapeutic effect of the agent being evaluated. As a result,
1
it is difﬁcult to determine whether the results obtained in
explanatory trials could be reproduced in a “real-life”
clinical setting.
Many trials have both pragmatic and explanatory
elements. Thorpe et al devised the pragmatic-
explanatory continuum indicator summary (PRECIS) tool
to assist trial design by clarifying whether a given research
methodology is pragmatic or explanatory, and to ensure
design decisions matched the intended trial purpose.11
This was later reﬁned to create PRECIS-2, developed
with the help of more than 80 international trialists, clini-
cians, and policymakers.12 The PRECIS-2 has 9 domains,
including eligibility, recruitment, setting, organization,
ﬂexibility: delivery, and ﬂexibility: adherence, follow-
up, primary outcome, and primary analysis (Table 1),
which are scored on a 5-point Likert scale, with one being
very explanatory and 5 very pragmatic according to
guidelines provided.12 Although created to assist trialists
to design trials that would align with the trial’s intended
purpose (pragmatic or explanatory), the PRECIS-2 tool
has been used also to rate the pragmatism of already
conducted RCTs with good interrater reliability.13
When making decisions involving treatment, clinicians
need to consider available evidence and determine
whether this evidence is relevant to the particular patient
to be treated. However, patients evaluated in clinical
practice and in need of treatment will not always fulﬁll the
criteria set in the trials providing the evidence. In this case,
the efﬁcacy of the particular treatment under consideration
is unknown. The more pragmatic the trials from which the
evidence has been gathered, the more likely it is that the
trials’ outcomes would be applicable to patients seen in
clinical practice.
The current study aimed at assessing the pragma-
tism of landmark RCTs evaluating ranibizumab for the
treatment of DME, using the PRECIS-2 tool, deter-
mining what proportion of patients seen in clinic meet
the eligibility criteria set in these RCTs, and evaluating
whether outcomes differ based on whether or not
patients fulﬁll the eligibility criteria.
Methods
Ranibizumab trials were chosen for evaluation, as
this drug was the ﬁrst licensed anti–vascular endothelial
growth factor agent approved for the treatment of DME,
and subsequently, most patients in our clinics would
have received this treatment during the study period.
Three published landmark RCTs investigating the
efﬁcacy of intravitreal ranibizumab for the treatment of
DME were selected, as follows:
1. The Protocol I of the Diabetic Retinopathy Clinical
Research Network (DRCRnet) comparing ranibizu-
mab plus prompt or deferred laser or triamcinolone
plus prompt laser for the treatment of DME.7
2. The Protocol T of the DRCRnet comparing aﬂiber-
cept, bevacizumab, and ranibizumab for DME.6
3. The RESTORE study, comparing ranibizumab
monotherapy or combined with laser versus laser
monotherapy for DME.8
RISE and RIDE were also RCTs evaluating ranibi-
zumab for the treatment of DME. In RISE and RIDE,
injections of ranibizumab were given monthly to all
patients for a period of 2 years. This strategy differs
greatly from that used in clinical practice, and thus, it
was decided not to include these RCTs in the current
study.
Table 1. PRECIS-2 Tool: Domains and Their Description
Domain Description
Eligibility Who is selected to participate in
the trial?
Recruitment How are participants recruited into
the trial?
Setting Where is the trial being conducted?
Organization What expertise and resources are
needed to deliver the
intervention?
Flexibility: delivery How should the intervention be
delivered?
Flexibility:
adherence
What measures are in place to
make sure participants adhere to
the intervention?
Follow-up How closely are participants
followed up?
Primary outcome How relevant is it to participants?
Primary analysis To what extent are all data
included?
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The PRECIS-2 tool was used to score the three selected
RCTs; 2 independent graders (N.L. and G.V.) scored each
trial based on the nine PRECIS-2 domains (Table 1). The
average of the scores given by each of the graders to each
of the included trials where plotted in the PRECIS-2
wheel. Scores were allocated considering the guidance
provided by PRECIS-2.12 If the scores given by the
graders differed considerably (i.e., larger than two points),
discrepancies were discussed and scores were moderated
accordingly.
For all three trials, “ﬂexibility: adherence” was
deemed not to be relevant, as the intervention was being
administered directly by the health care provider, rather
than being dependent on patient’s self-administration.
For this reason, this domain was not scored, and the
maximum possible overall score was 40 rather than 45.
A cohort of patients was established to address the
second objective of the study, namely the proportion of
patients meeting the eligibility criteria set on the selected
RCTS and whether outcomes after treatment with
ranibizumab differ based on whether or not patients
fulﬁll eligibility criteria set in the three selected RCTs.
This patient cohort consisted of all consecutive eligible
patients evaluated in a specialized DME clinic at the
Belfast Health and Social Care Trust, Belfast, Northern
Ireland, who had received their ﬁrst dose of ranibizumab
between March 1, 2014, and March 31, 2015. Patients
were identiﬁed through an electronic diagnostic database.
To be eligible, they should have received the minimum
loading dose (considered to be three injections) and be
followed for a minimum period of 12 months. Patients
were excluded if they received any other intravitreal
agent, such as aﬂibercept or dexamethasone, during the
follow-up period. The study was registered with the
Audit Department of the Belfast Health and Social Care
Trust (audit approval number 5170) and was deemed
exempt from full ethical review. The authors conﬁrm that
data collection conformed to the local policy at the
Belfast Health and Social Care Trust. Patients considered
eligible for this audit were given a study number to
ensure conﬁdentiality was maintained.
In keeping with procedures of standard clinical
practice, all patients had an ocular examination, which
included refraction at baseline and best-corrected
visual acuity (BCVA) measured with Early Treatment
Diabetic Retinopathy Study (ETDRS) visual acuity
charts, intraocular pressure check, and slit-lamp bio-
microscopy. Spectral domain optical coherence
tomography scans were routinely obtained by trained
ophthalmic photographers at every clinic visit using
commercially available equipment (Heidelberg Spec-
tralis; Heidelberg Engineering, Heidelberg, Germany).
Intravitreal injections were performed in a clean room;
topical anesthesia and povidone 5% were used in all
cases before the procedure. The treatment protocol
consisted of three ranibizumab injections at 4-weekly
intervals followed by a pro re nata regimen thereafter.
All three RCTs selected provided clear eligibility
(inclusion and exclusion) criteria. Based on these
inclusion and exclusion criteria, which included ocular
and systemic factors, each patient in the established
cohort was evaluated by two investigators (S.S. and
J.L.Y.) to determine whether or not they would have
been eligible to be included in each of these trials. A
patient was considered to have met the inclusion
criteria only if all selection criteria (ocular and
systemic) were fulﬁlled at the time of initiation of
ranibizumab treatment. For patients who did not meet
the eligibility criteria of the landmark trials, the
reasons for exclusion were recorded.
For all patients, the following information was
extracted: age, sex, diagnosis (Type I or Type II
diabetes mellitus), visual acuity (ETDRS letter score)
at baseline and at 12 months, number of injections by
12 months, and CRT at baseline and at 12 months.
The following outcomes were determined and
compared between “eligible” (fulﬁlled all eligibility
criteria) and “ineligible” (did not fulﬁll one or more
of the eligibility criteria) patients: change in BCVA
from baseline to Month 12 and change in CRT from
baseline to Month 12.
Univariable and multivariable regression analyses,
taking into account within-subject correlation as ran-
dom effects in linear mixed models, were undertaken to
assess differences in outcomes between “eligible” and
“ineligible” patients of the patient cohort. Multivariable
analyses were adjusted by progressively adding base-
line BCVA, baseline CRT, and number of injections
received to the univariable model that included eligibil-
ity status only. All analyses were conducted using Stata
15.1 (StataCorp, College Station, TX).
Results
Overall, the three RCTs selected were scored as
more pragmatic than explanatory (Table 2 and Figure
1). The DRCRnet Protocol T study6 was scored as the
most pragmatic of all the RCTs selected, with the
RESTORE study8 being rated as least pragmatic over-
all. All three trials were rated as rather pragmatic or
very pragmatic for eligibility, recruitment, setting,
organization, primary outcome, and primary analysis.
Flexibility in delivery of the intervention and
follow-up was felt to be rather explanatory for all
three trials, as monthly appointments are difﬁcult or
not feasible in many public health care systems, such
as those established in Europe. The treatment and
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retreatment criteria set in the RESTORE study8 was
considered to be less stringent than those set out by the
DRCR network; therefore, this domain (ﬂexibility:
delivery) was scored as more pragmatic than that of
the DRCRnet trials.
With respect to subject eligibility, the graders made
note of the lower tolerance for blood pressure (BP)
levels in the RESTORE study; BP levels for included
patients had to be,160/101, compared with,181/111
for the DRCRnet trials, which was felt to be a stricter
limit than that applied in most clinical settings.
A cohort of 176 patients (216 eyes) was established,
based on the criteria set and presented in the “Meth-
ods” section (see above). Demographics and baseline
characteristics of the patients included in this cohort
have been summarized in Table 3.
Almost three-quarter of the eyes in the cohort were
found to fulﬁll the eligibility criteria set in at least one
of the three trials included (154/216, 71.3%); just under
half (102/216, 47.2%) were found to be eligible for all
three (Table 4). The greatest proportion of eyes met
eligibility criteria set in DRCRnet Protocol T (63.0%),
with least number of eyes fulﬁlling the eligibility crite-
ria set in the RESTORE study (55.6%). Approximately
60.6% of eyes were eligible for DRCRnet Protocol I.
Overall, 74 (34.3%), 69 (31.9%), and 73 (33.8%) eyes
did not fulﬁll eligibility criteria to be included in
DRCRnet Protocols I and T and the RESTORE study,
respectively, for ocular reasons. The main reasons for
exclusion were low or high BCVA (for Protocols I and T,
DRCR.net: n = 26, 10%; for RESTORE: n = 44, 20.4%)
Table 2. PRECIS-2 Scores for Landmark Trials
Mean of the Scores Given by 2 Graders
for Each Domain of the PRECIS-2 Tool
DRCR.net
Protocol I
DRCRnet
Protocol T RESTORE
Eligibility 5 5 4
Recruitment 5 5 5
Setting 5 5 4
Organization 4 4 4
Flexibility:
delivery
2 2 3
Flexibility:
adherence
— — —
Follow-up 2 3 2
Primary
outcome
5 5 5
Primary
analysis
5 5 4
Total 33/40 34/40 31/40
Score: 1, very explanatory; 2, rather explanatory; 3, equally
pragmatic and explanatory; 4, rather pragmatic; and 5, very
pragmatic.
Fig. 1. PRECIS-2 wheels illustrating the pragmatism of the RCTs included in the study, generated through www.precis-2.org. A. Protocol I,
DRCRnet.7 B. Protocol T, DRCRnet.6 C. RESTORE study.8.
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and panretinal photocoagulation undertaken within 4 to 6
months of inclusion (for Protocols I and T, DRCR.net: n
= 31, 14.5%; for RESTORE: n = 27, 12.5%). For both
the DRCRnet trials, eyes were most often excluded
because of ocular factors, particularly recent laser (Table
5). No eye was excluded due to inﬂammation or infection
or other ocular comorbidity.
Overall, 15 (6.9%), 15 (6.9%), and 45 (20.8%) eyes
[of 11 (6.3%), 11 (6.3%), and 33 (48.8%) patients] did
not fulﬁll eligibility criteria set in DRCRnet Protocols I
and T and the RESTORE study, respectively, because
of systemic factors. The RESTORE study had a more
stringent BP requirement (,160/100), and this alone
excluded 13.9% (30/216) of eyes from the study cohort.
The entire patient study cohort had an average
baseline ETDRS letter score of 60.3 (±16.3) and
gained an average of 6.4 letters (4.9–7.9; 95% conﬁ-
dence interval [CI]) by 12 months.
Univariable regression analysis demonstrated that
eligible patients, on average, gained more letters by
Month 12 than ineligible patients (Tables 6 and 7).
This was most pronounced for the DRCRnet Protocol
T study in which patients meeting eligibility criteria
gained on average 7.5 letters when compared with 4.6
letters in those that did not fulﬁll them.
The average baseline CRT for the study cohort was
484 mm (±134), with an average change in CRT of
2152 mm (2178 to2125; 95% CI) by 12 months. No
statistically signiﬁcant difference in CRT change was
detected between eligible and ineligible subjects for
any set of eligibility criteria.
Differences in BCVA or CRT showed modest
changes in multivariable models progressively adjusting
for baseline BCVA, CRT, or the number of injections,
with no statistically signiﬁcant differences detected.
Considering the potential effect of a broader range
of baseline BCVA in ineligible patients compared with
eligible patients (5–85 letters [Snellen equivalent 20/
800–20/20] for the study cohort versus 24 to 78 letters
[Snellen equivalent 20/320–20/32] for Protocol I; 24
to 78 letters [Snellen equivalent 20/320–20/32] for
Protocol T; and 39 to 78 letters [Snellen equivalent
20/160–20/32] for RESTORE study), which may
have been difﬁcult to control for in regression
analyses, we then calculated the mean difference in
BCVA gain in a group of 179 eyes of 151 patients
who had baseline BCVA between 34 (Snellen
equivalent of 20/200) and 78 letters (Snellen
equivalent 20/32). For this group also, results
remained unchanged, and no statistically signiﬁcant
differences in BCVA gain were observed between
eligible and ineligible eyes, when adjusted for
baseline BCVA, CRT, and number of injections
received (22.2 letters, 95% CI: 25.4 to 20.9 letters,
P = 0.167 for DRCRnet Protocol I, 23.2 letters, 95%
CI: 26.4 to 0.1 letters, P = 0.056 for DRCRnet
Protocol T, and 22.4 letters, 95% CI: 25.5 to 0.7
letters, P = 0.133 for the RESTORE study).
In a linear mixed model, adjusting for baseline
BCVA and baseline CRT, exclusion due to any ocular
criterion was not associated with visual change for any
study (P . 0.1), ruling out effects larger than ± 3
letters. However, exclusion due to any systemic crite-
rion was associated with 212 letters worse outcome in
DRCRnet Protocols I and T (P , 0.001 for both) but
not in the RESTORE study (22.4 letters, P = 0.160) in
ineligible patients. This ﬁnding remained when adjust-
ing for the number of injections received.
Among ocular criteria considered simultaneously in
a regression model, only the single individual with
Table 3. Demographics and Characteristics of the Study
Cohort
Patient Characteristics Mean ± SD
Mean age ± SD (years) 65.4 ± 12.0
Sex (% male) 106 (65.4)
Diabetes type, n (%)
Type I 31 (19.1)
Type II 131 (80.9)
Mean baseline ETDRS letter score
for BCVA (Snellen equivalent) ±
SD
60.3 (20/63) ± 16.3
Study cohort: 216 eyes of 176 patients.
Table 4. Proportion of Study Cohort Eyes and Patients Meeting Eligibility Criteria for Entering DRCRnet Protocols I and T
and the RESTORE Study
Ocular Criteria Systemic Criteria All Criteria
% Eyes Included (n Eyes,
n Patients)
% Eyes Included (n Eyes,
n Patients)
% Eyes Included (n Eyes,
n Patients)
Protocol I, DRCR.
net
65.7 (142/216, 117/176) 93.1 (201/216, 165/175) 60.6 (131/216, 107/176)
Protocol T, DRCR.
net
68.1 (147/216, 119/176) 93.1 (201/216, 165–176) 63.0 (136/216, 110/176)
RESTORE study 66.2 (143/216, 115/176) 79.2 (171/216, 143–176) 55.6 (120/216, 95/176)
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visual gain of 52 letters in whom DME was not the
primary cause of visual loss (Table 5) signiﬁcantly
inﬂuenced overall change of vision (P , 0.001). After
the exclusion of this subject, among systemic criteria
with at least one count in the model and after adjusting
for baseline BCVA and CRT, according to DRCRnet
Protocols I and T, previous cardiovascular events ac-
counted for worse BCVA change by 215 letters (95%
CI: 227 to 27, P , 0.001) and elevated systemic BP
accounted by 29 letters (95% CI: 216 to 23; P =
0.007). For the RESTORE study, there was no exclu-
sion due to recent cardiovascular events, and the
threshold criterion for exclusion due to BP criteria
was lower and was not associated with BCVA change
(23 letters, 95% CI: 26.8 to +0.7 letters, P = 0.092).
Discussion
All three selected landmark RCTs evaluating ranibi-
zumab for DME, namely DRCRnet protocols I and T and
the RESTORE study, were found to be more pragmatic
than explanatory using the PRECIS-2 tool, with Protocol
T being the most pragmatic of all. The RESTORE study
was felt to be less pragmatic overall, mainly due to
stricter eligibility criteria, excluding patients with BP
.160/100 mmHg, recent change in antihypertensive
medications or a previous history of stroke. Both
DRCRnet Protocols I and T were considered to be very
pragmatic in terms of their criteria for patient eligibility.
Despite the fact that all selected RCTs were graded as
being more pragmatic than explanatory, it was found that
only 55.6% to 63.0% of eyes fulﬁlled the eligibility
Table 5. Most Frequent Reasons for Patients in the Study
Cohort Not to Meet Eligibility Criteria Set in DRCRnet
Protocols I and T and the RESTORE Study
Excluded n (%)
Protocol
I
Protocol
T RESTORE
Ocular
ETDRS letter score 26 (12) 26 (12) 44 (20)
CRT 5 (2) 5 (2) 0 (0)
DME not primary
cause of visual loss
1 (0.5) 1 (0.5) 1 (0.5)
IOP 6 (3) 0 (0) 5 (2)
Other DME treatment
(focal laser)
15 (7) 15 (7 6 (3)
Recent PRP 31 (14) 31 (14) 27 (12)
Ocular surgery 8 (4) 8 (4) 0 (0)
Systemic
Cardiovascular
disease
7 (3) 7 (3) 0 (0)
BP 8 (4) 8 (4) 30 (14)
Recent change in
antihypertensive
medication
0 (0) 0 (0) 21 (10)
PRP, panretinal photocoagulation; IOP, intraocular pressure; CRT,
central retinal thickness; DME, diabetic macular edema; BP, blood
pressure; ETDRS, Early Treatment Diabetic Retinopathy Study.
Table 6. Baseline Characteristics of the Study Cohort and Univariable Regression Analysis Comparing Outcomes of
“Eligible” and “Ineligible” Patients Based on Eligibility Criteria Set in DRCRnet Protocols I and T and the RESTORE Study
Patients n
(Eyes n)
Study
Cohort Protocol I, DRCRnet Protocol T, DRCRnet RESTORE Study
n. 176
(n. 216)
Eligible; n. 107
(n. 131)
Ineligible;
n. 69 (n. 75)
Eligible; n. 110
(n. 136)
Ineligible; n.66
(n. 80)
Eligible; n. 95
(n. 120)
Ineligible; n. 81
(n. 96)
Age 65.6 (12.0) 65.7 (12.0) 64.7 (12.1) 66.3 (12.2) 65.2 (11.9) 66.2 (11.7) 64.9 (12.3)
Diabetes Type 1
(%)
18.2 15.9 21.7 16.4 21.2 15.8 21
BCVA baseline 60.3 59.6 61.2 59.8 61.1 61.5 58.7
ETDRS score 20/63 20/63 20/63 20/63 20/63 20/63 20/80
Snellen
equivalent
16.3 13.1 20.3 13.1 20.7 11.3 20.9
BCVA 12 months 66.7 66.9 66.2 67.3 65.6 68.3 64.6
ETDRS score 20/50 20/50 20/50 20/50 20/50 20/50 20/50
Snellen
equivalent
15.6 12.3 19.6 12.3 20.0 12.5 18.7
CRT baseline 484 (134) 481 (129) 489 (141) 484 (130) 485 (141) 472 (121) 500 (148)
CRT 12 months 346 (97) 344 (96) 348 (100) 345 (96) 348 (101) 339 (85) 354 (111)
Injections 7.1 (2.2) 7.2 (2.2) 6.8 (2.4) 7.3 (2.2) 6.6 (2.3)* 7.1 (2.2) 7.0 (2.4)
BCVA change +6.4 +7.3 +5.0 +7.5 +4.6 +6.8 +5.9
0–12 months
(95% CI)†
(4.9–7.9) (5.4–9.2) (2.7–7.4) (5.6–9.3) (2.2–7.0) (4.9–8.8) (3.7–8.1)
CRT change 2152 2136 2137 2131 2143 2138 2133
0–12 months
(95% CI)†
(2178 to
2125)
(2162 to 2110) (2169 to
2105)
(2158 to 2104) (2173 to 2113) (2163 to 2112) (2166 to 2100)
*P , 0.05.
†As predicted by a mixed model accounting for within-subject correlation with no adjustment.
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criteria of the three RCTs selected. Nearly 30% of eyes
did not meet eligibility criteria for any of these RCTs.
Around a quarter of eyes failed to meet the inclusion
criteria set in these RCTs because they either had a level
of vision outside the established limits in the RCTs or
because they had recently received panretinal photoco-
agulation, indicating that there was proliferative diabetic
retinopathy present in addition to DME.
The difference in visual acuity gain between eligible
and ineligible patients consistently favored eligible
patients by about two ETDRS letters but never reached
statistical signiﬁcance. Of interest, point estimates were
unchanged after progressively adjusting by baseline
BCVA, CRT, and number of intravitreal injections
received. The precision of these estimates ruled out
a difference in mean BCVA gain by no more than 5
letters favoring eligible patients, a limit that is acceptable
to rule out clinically important differences in visual
change.14 However, differences in CRT between eligible
and ineligible patients were negligible, and their precision
excluded maximum differences by no more than 50 mm.
All this considered, we conclude that trial ineligibility in
our clinical setting did not seem to have a meaningful or
large effect on visual and anatomical outcomes in patients
with DME undergoing of ranibizumab treatment.
The subgroup of patients with ocular exclusion criteria,
mainly high or low visual acuity, did not show differences
in visual outcomes when baseline BCVA was accounted
for. On the contrary, patients with systemic exclusion
criteria, particularly high BP or a change in antihyperten-
sive medication, showed signiﬁcantly less gain in vision
than the others. This subgroup analysis, however, was
exploratory and should be considered with caution and
conﬁrmed in further studies, given the relatively small
number of patients in this subgroup. Nonetheless, there is
strong evidence from cohort studies that uncontrolled BP
increases the chances of progression of diabetic retinop-
athy.15–17 Our study suggests that a sizeable fraction of
patients in need of anti–vascular endothelial growth factor
injections for DME may suffer from visual loss despite
appropriate treatment due to systemic cardiovascular
disease and uncontrolled BP. This ﬁnding underlines the
importance of an integrated approach by both diabetolo-
gists and ophthalmologists to patients with vision-
threatening diabetic retinopathy.
Despite the high proportion of treated patients in the
clinical cohort presented herein who did not meet the
eligibility criteria set in the DRCR.net Protocols I and T
and RESTORE, no statistically signiﬁcant differences in
outcomes were found between “eligible” and “ineligible”
patients. This ﬁnding is reassuring for clinicians. Some of
the reasons for excluding patients from clinical trials may
not relate to a predicted lack of efﬁcacy in groups of
patients excluded but more so to their potential confound-
ing effect. It has been shown that people with a higher
baseline visual acuity will be expected to have higher ﬁnal
vision after treatment,18–20 which would support initiating
early treatment, when vision is still good. However, there
would be less chance for an improvement in visual acuity,
given the good level of vision at baseline. In the ETDRS,
macular laser photocoagulation was shown to prevent
visual loss but did not improve vision; 85% of patients
included in this trial had visual acuity of $20/40 at base-
line.21 Similarly, patients in the Protocol T study with an
Table 7. Multivariable Regression Models Comparing Patients Fulﬁlling (“Eligible”) and Not Fulﬁlling (“Ineligible”) Eligibility
Criteria Set in the DRCR.net Protocol I and T Studies and the RESTORE Study
Model 1:
Unadjusted
Model 2 (Adjusted for
Baseline BCVA)
Model 3 (Adjusted for
Baseline BCVA and
CRT)
Model 4 (Adjusted for
Baseline BCVA and
CRT as well as Number
of Injections Received
from Baseline to
Month 12)
DRCRnet Protocol I:
difference in eligible
versus ineligible eyes
BCVA change +2.2 (20.7 to +5.3) +1.9 (20.9 to +4.6) +1.9 (20.8 to +4.7) +1.8 (20.9 to +4.6)
CRT change 0 (242 to +42) 26 (235 to +47) 28 (235 to +19) 27 (234 to +20)
DRCRnet Protocol T:
difference in eligible
versus ineligible eyes
BCVA change +2.9 (20.1 to +5.9) +2.6 (20.2 to 5.3) +2.6 (20.2 to +5.4) +2.5 (20.3 to +5.3)
CRT change +5.8 (247 to +36) +2 (242 to +39) 24 (231 to +22) 22 (229 to +25)
RESTORE study:
difference in eligible
versus ineligible eyes
BCVA change +0.9 (22.0 to +3.9) +1.7 (21.0 to 4.4) +1.9 (20.9 to +4.6) +1.9 (20.8 to +4.7)
CRT change 213 (228 to +43) 6 (233 to +45) 212 (239 to +14) 212 (238 to +14)
PRAGMATISM OF RCTs OF RANIBIZUMAB IN DME  STEWART ET AL 7
initial visual acuity score between 69 and 78 letters
(Snellen equivalent 20/40–20/32) gained signiﬁcantly
fewer letters than those with an initial letter score of 69
letters (#20/50) or less.6 A DRCRnet trial on anti–
vascular endothelial growth factor (anti-VEGF) therapy
in people with very good levels of vision is now under-
way and would provide information in the future on this
group.22
This study has several limitations, including the
retrospective nature of the study cohort and the short-
term follow-up at which outcomes were tested (12
months). Although we included a large number of eyes
in the study, an even larger cohort would have increased
the power of our study. A post hoc power calculation
considering 72 ineligible versus 144 eligible eyes with an
SD of 16 letters, as we observed at baseline, would have
had 80% power to detect a difference of 6.5 ETDRS
letters and 90% power to detect a difference of 7.5 letters.
Thus, the sample size included should have given us
enough power to detect clinically relevant differences if
these had existed.
Strengths include the identiﬁcation of consecutive
eligible cases through an electronic database, the relatively
high number of eyes included in the analysis (n = 216)
and the very detailed evaluation of inclusion and exclu-
sion criteria set in each of the three selected RCTs for
each patient in the study cohort. When examining the
differences in outcomes between eligible and ineligible
patients, it may have been interesting to compare the
inﬂuence of HbA1c as marker of glycemic control. How-
ever, HbA1c has not been found to affect visual outcomes
in patients with DME treated with intravitreal anti-VEGF
factors.19,20,23
Many patients with DME treated with ranibizumab
in the clinical setting did not meet the eligibility
criteria set in the RCTs demonstrating the efﬁcacy of
this treatment. Despite this, no apparent differences in
outcomes (BCVA and CRT) were found between
individuals fulﬁlling eligibility criteria and those that
did not. This information may be used by clinicians to
decide whether or not to initiate treatment with
ranibizumab in patients with DME in their clinical
practice and for the counseling of these patients.
Key words: diabetic macular edema (DME), vascu-
lar endothelial growth factors (VEGF), Ranibizumab,
anti-VEGF, clinical trial design.
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